Benzodiazepines, Urine, Quantitative
Ordering Recommendation
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Random urine.  
Specimen Preparation
Transfer 0.5 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 0.3 mL)  
Storage/Transport Temperature
Room temperature.  
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles.  
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years  
Reference Interval
Drugs Covered Cutoff Concentrations
Alprazolam 5 ng/mL
Alpha-​hydroxyalprazolam 5 ng/mL
Chlordiazepoxide 20 ng/mL
Clonazepam 5 ng/mL
7-​aminoclonazepam 5 ng/mL
Diazepam 20 ng/mL
Lorazepam 20 ng/mL
Midazolam 20 ng/mL
Alpha-​hydroxymidazolam 20 ng/mL
Nordiazepam 20 ng/mL
Oxazepam 20 ng/mL
Temazepam 20 ng/mL
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Drugs covered:
alprazolam, alpha-hydroxyalprazolam, chlordiazepoxide, clonazepam, 7-aminoclonazepam, diazepam, lorazepam, midazolam, alpha-hydroxymidazolam, nordiazepam, oxazepam and temazepam..

Positive cutoff:
20 ng/mL unless specified below:
Alprazolam 5 ng/mL
Alpha-hydroxyalprazolam 5 ng/mL
Clonazepam 5 ng/mL
7-aminoclonazepam 5 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
CPT Code(s)
80347; (Alt code: G6031)
Component Test Code*Component Chart NameLOINC
2007834Diazepam, Urn, Quant16227-1
2007835Oxazepam, Urn, Quant3886-9
2007836Temazepam, Urn, Quant20559-1
2007837Nordiazepam, Urn, Quant16228-9
2007838Lorazepam, Urn, Quant17088-6
2007839Alprazolam, Urn, Quant59615-5
2007840Alpha-hydroxyalprazolam, Urn, Quant16348-5
2007841Clonazepam, Urn, Quant16229-7
20078427-aminoclonazepam, Urn, Quant51776-3
2007846Midazolam, Urn, Quant16233-9
2007847Chlordiazepoxide, Urn, Quant20522-9
2008511Alpha-hydroxymidazolam, Urn, Quant59590-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Pain Management, Benzodiazepines, Quantitative, w/ medMATCH, Urine (Drugs of Abuse Confirmation/Quantitation-Benzodiazepines-Urine)
  • Pain Management, Benzodiazepines, w/Confirmation w/med MATACH, Urine (Drugs of Abuse Confirmation/Quantitation-Benzodiazepines-Urine)